1 / 18

Region II Infertility Prevention Project Advisory Committee May 16-17, 2007 New York, New York

Region II Infertility Prevention Project Advisory Committee May 16-17, 2007 New York, New York. Steven J. Shapiro Infertility Prevention Project Coordinator CDC/NCHHSTP/DSTDP/PTB (proposed)

shae
Download Presentation

Region II Infertility Prevention Project Advisory Committee May 16-17, 2007 New York, New York

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Region II Infertility Prevention Project Advisory CommitteeMay 16-17, 2007New York, New York Steven J. Shapiro Infertility Prevention Project Coordinator CDC/NCHHSTP/DSTDP/PTB (proposed) Disclaimer: The findings and conclusions in this presentation are those of the author and do not necessarily represent the views of the Centers for Disease Control and Prevention.

  2. Performance MeasuresData Review • Region II and National Summary Data • Data Verification • Prevalence Monitoring and Performance Measure Data • Regional Summary • Project Area Snapshot

  3. Performance MeasureIPP CS1 Among clients of IPP Family Planning clinics, the proportion of women with positive chlamydia tests treated within 14 and 30 days of the date of specimen collection.

  4. IPP CS 1 (Chlamydia) Results

  5. Performance MeasureIPP CS2 Among clients of IPP Family Planning clinics, the proportion of women with positive gonorhea tests treated within 14 and 30 days of the date of specimen collection.

  6. IPP CS 2 (Gonorrhea) Results

  7. Performance MeasureCSPS MLS1 Proportion of female admittees to large juvenile detention centers tested for chlamydia.

  8. CSPS MLS1 (JDC Screening) Results

  9. Data Verification • Performance Measures Guidance: • IPP Family Planning Clinics: All family planning clinics that report data as part of the Chlamydia Prevalence Monitoring Project, regardless of whether they are integrated clinics or not. • Denominator: Total number of women who tested positive for chlamydia (at those family planning clinics) • In other words: If ten FP clinics in a jurisdiction report 500 CT positives and 9500 CT negatives to the prevalence monitoring database, then the denominator for the performance measure should be 500.

  10. Prevalence Monitoring v. Performance MeasureFemales in IPP Family Planning ClinicsChlamydia and Gonorrhea 2005Region II Summary

  11. Reasons for Differences • 2005 data • If Prev. Monitoring > Perf. Measures • Prevalence Monitoring data includes only those clinics who reported more than a total of 25 tests during the year • Not counting integrated clinics • If Prev. Monitoring < Perf. Measures • Non-prevalence monitoring FP sites submitting data for performance measures • Counting non-FP sites • ???

  12. Prevalence Monitoring v. Performance MeasureFemales in IPP Family Planning ClinicsChlamydia 2005

  13. Prevalence Monitoring v. Performance MeasureFemales in IPP Family Planning ClinicsGonorrhea 2005

  14. Questions?

More Related